CCRC: Phase I Study of the Combination of Temsirolimus (CCI-779) and Pazopanib (GW786034) in Patients With Advanced Solid Tumours.

Trial Profile

CCRC: Phase I Study of the Combination of Temsirolimus (CCI-779) and Pazopanib (GW786034) in Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2012

At a glance

  • Drugs Pazopanib; Temsirolimus
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Mar 2012 GlaxoSmithKline and Pfizer added as trial sponsor and lead trial centres as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Actual patients number is 8 as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top